Neoadjuvant Pembrolizumab Plus Chemotherapy Yields 37.5% Major Pathologic Response in Resectable NSCLC; Exploratory Spatial Profiling Separates Myeloid- and Lymphoid-Enriched Responders in a Single-Arm Phase II Trial